{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T17:39:22Z","timestamp":1789925962214,"version":"4.0.1"},"reference-count":77,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,12,29]],"date-time":"2024-12-29T00:00:00Z","timestamp":1735430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Hepatitis C virus (HCV) infects both pediatric and adult populations and is an important cause of chronic liver disease worldwide. There are differences in the screening and management of HCV between pediatric and adult patients, which have been highlighted in this review. Direct-acting antiviral agents (DAA) have made the cure of HCV possible, and fortunately, these medications are approved down to three years of age. However, treatment in the pediatric population has its own set of challenges. The World Health Organization (WHO) has made a pledge to eliminate HCV as a public health threat by 2030. Despite this, HCV continues to remain a global health burden, leading to cirrhosis as well as hepatocellular carcinoma, and is a reason for liver transplantation in the adult population. Although rare, these complications can also affect the pediatric population. A variety of new technologies t have become available in the current era and can advance our understanding of HCV are discussed. Artificial intelligence, machine learning, liver organoids, and liver-on-chip are some examples of techniques that have the potential to contribute to our understanding of the disease and treatment process in HCV. Despite efforts over several decades, a successful vaccine against HCV has yet to be developed. This would be an important tool to help in worldwide efforts to eliminate the virus.<\/jats:p>","DOI":"10.3390\/pathogens14010011","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T04:10:23Z","timestamp":1735618223000},"page":"11","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Hepatitis C Virus\u2013Pediatric and Adult Perspectives in the Current Decade"],"prefix":"10.3390","volume":"14","author":[{"given":"Nanda","family":"Kerkar","sequence":"first","affiliation":[{"name":"Massachusetts General Brigham for Children, 175 Cambridge Street, Boston, MA 02114, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0780-1954","authenticated-orcid":false,"given":"Kayla","family":"Hartjes","sequence":"additional","affiliation":[{"name":"Massachusetts General Brigham for Children, 175 Cambridge Street, Boston, MA 02114, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,29]]},"reference":[{"key":"ref_1","unstructured":"Bhattacharya, D., Aronsohn, A., Price, J., Lo Re, V., and AASLD-IDSA HCV Guidance Panel (2023). Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/MPG.0000000000002814","article-title":"Hepatitis C in 2020: A North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper","volume":"71","author":"Leung","year":"2020","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/j.jhep.2016.08.002","article-title":"Who to test and how to test for chronic hepatitis C infection\u20142016 WHO testing guidance for low- and middle-income countries","volume":"65","author":"Easterbrook","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1126\/science.2523562","article-title":"Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome","volume":"244","author":"Choo","year":"1989","journal-title":"Science"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.antiviral.2014.12.014","article-title":"Surveying the global virome: Identification and characterization of HCV-related animal hepaciviruses","volume":"115","author":"Scheel","year":"2015","journal-title":"Antivir. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/498310b","article-title":"Virology: The virus whose family expanded","volume":"498","author":"Pybus","year":"2013","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/cid\/ciu447","article-title":"Vertical transmission of hepatitis C virus: Systematic review and meta-analysis","volume":"59","author":"Benova","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0140-6736(95)90277-5","article-title":"Mother-to-infant transmission of hepatitis C virus. Lombardy Study Group on Vertical HCV Transmission","volume":"345","author":"Zanetti","year":"1995","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s12072-015-9630-4","article-title":"Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries","volume":"9","author":"Omata","year":"2015","journal-title":"Hepatol. Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1136\/bmj.327.7423.1075","article-title":"Use of injections in healthcare settings worldwide, 2000: Literature review and regional estimates","volume":"327","author":"Hutin","year":"2003","journal-title":"BMJ"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Saludes, V., Bordoy, A.E., Yela, E., Turu, E., Not, A., Lopez-Corbeto, E., and Martr\u00f3, E. (2023). Incidence and molecular epidemiology of hepatitis C virus reinfection in prisons in Catalonia, Spain (Re-HCV study). Sci. Rep., 13.","DOI":"10.1038\/s41598-023-42701-1"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","article-title":"Global epidemiology and genotype distribution of the hepatitis C virus infection","volume":"61","author":"Gower","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/jvh.13060","article-title":"Awareness of chronic viral hepatitis in the United States: An update from the National Health and Nutrition Examination Survey","volume":"26","author":"Kim","year":"2019","journal-title":"J. Viral Hepat."},{"key":"ref_14","unstructured":"(2024, December 24). Hepatitis C Surveillance 2022, Available online: https:\/\/www.cdc.gov\/hepatitis-surveillance-2022\/hepatitis-c\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/hepatitis\/statistics\/2022surveillance\/hepatitis-c.htm."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"643","DOI":"10.4254\/wjh.v6.i9.643","article-title":"Vertical transmission of hepatitis C virus: Current knowledge and perspectives","volume":"6","author":"Yeung","year":"2014","journal-title":"World J. Hepatol."},{"key":"ref_16","unstructured":"Centers for Disease Control and Prevention (CDC) (2024, December 24). Test for Hepatitis C During Every Pregnancy, Available online: https:\/\/archive.cdc.gov\/www_cdc_gov\/knowmorehepatitis\/hcp\/Test-For-HepC-During-Pregnancy.htm."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jpeds.2017.09.016","article-title":"Increasing Prevalence of Hepatitis C among Hospitalized Children Is Associated with an Increase in Substance Abuse","volume":"192","author":"Barritt","year":"2018","journal-title":"J. Pediatr."},{"key":"ref_18","first-page":"537","article-title":"Hepatitis C virus infection among adolescents and young adults:Massachusetts, 2002\u20132009","volume":"60","author":"Onofrey","year":"2011","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7204a1","article-title":"CDC Recommendations for Hepatitis C Testing Among Perinatally Exposed Infants and Children\u2014United States, 2023","volume":"72","author":"Panagiotakopoulos","year":"2023","journal-title":"MMWR Recomm. Rep."},{"key":"ref_20","unstructured":"Polaris Observatory HCVC (2017). Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study. Lancet Gastroenterol. Hepatol., 2, 161\u2013176."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/s41598-017-17936-4","article-title":"Characterizing hepatitis C virus epidemiology in Egypt: Systematic reviews, meta-analyses, and meta-regressions","volume":"8","author":"Kouyoumjian","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s40249-023-01106-y","article-title":"Molecular epidemiology of hepatitis C virus genotypes in different geographical regions of Chinese mainland and a phylogenetic analysis","volume":"12","author":"Tang","year":"2023","journal-title":"Infect. Dis. Poverty"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1001\/jama.284.4.450","article-title":"The natural history of hepatitis C virus infection: Host, viral, and environmental factors","volume":"284","author":"Thomas","year":"2000","journal-title":"JAMA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jhep.2018.11.013","article-title":"Epidemiology and natural history of hepatitis C virus infection among children and young people","volume":"70","author":"Modin","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/hepr.14032","article-title":"Natural history and clinical features of hepatitis C virus infection during childhood: A nationwide, observational survey in Japan","volume":"54","author":"Nakano","year":"2024","journal-title":"Hepatol. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1053\/j.gastro.2008.02.082","article-title":"Long-term course of chronic hepatitis C in children: From viral clearance to end-stage liver disease","volume":"134","author":"Bortolotti","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1002\/hep.22094","article-title":"Pathology of chronic hepatitis C in children: Liver biopsy findings in the Peds-C Trial","volume":"47","author":"Goodman","year":"2008","journal-title":"Hepatology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1056\/NEJM200001273420414","article-title":"Hepatitis C in children","volume":"342","author":"Birnbaum","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/hep.22375","article-title":"Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-analysis and meta-regression","volume":"48","author":"Thein","year":"2008","journal-title":"Hepatology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.1016\/j.ajt.2024.01.014","article-title":"OPTN\/SRTR 2022 Annual Data Report: Liver","volume":"24","author":"Kwong","year":"2024","journal-title":"Am. J. Transpl."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.30830","article-title":"Ledipasvir-Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis, C","volume":"71","author":"Schwarz","year":"2020","journal-title":"Hepatology"},{"key":"ref_33","unstructured":"American Association for the Study of Liver Diseases (AASLD), and Infectious Diseases Society of America (IDSA) (2020). Simplified HCV Treatment Algorithm for Treatment-Naive Adults with Compensated Cirrhosis, IDSA. Available online: https:\/\/www.hcvguidelines.org\/sites\/default\/files\/full-guidance-pdf\/AASLD-IDSA_HCV-Guidance_TxN-Simplified-Tx-No-Cirr_e.pdf."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1111\/liv.15637","article-title":"Efficacy and safety of treatment with sofosbuvir\/velpatasvir in patients aged 6\u201318\u2009years with chronic hepatitis C-Results of the PANDAA-PED study","volume":"43","author":"Talarek","year":"2023","journal-title":"Liver Int."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1053\/jhep.2002.36806","article-title":"Natural history of chronic hepatitis C","volume":"36","author":"Seeff","year":"2002","journal-title":"Hepatology"},{"key":"ref_36","unstructured":"Centers for Disease Control and Prevention (CDC) (2024, December 24). Clinical Screening and Diagnosis for Hepatitis, C, Available online: https:\/\/www.cdc.gov\/hepatitis-c\/hcp\/diagnosis-testing\/index.html."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Jarasvaraparn, C., Hartley, C., and Karnsakul, W. (2024). Updated Clinical Guidelines on the Management of Hepatitis C Infection in Children. Pathogens, 13.","DOI":"10.3390\/pathogens13020180"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.30830","article-title":"Ledipasvir-Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C","volume":"71","author":"Schwarz","year":"2019","journal-title":"Hepatology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/hep.31841","article-title":"Pharmacokinetics, Safety, and Efficacy of Glecaprevir\/Pibrentasvir in Children with Chronic HCV: Part 2 of the DORA Study","volume":"74","author":"Jonas","year":"2021","journal-title":"Hepatology"},{"key":"ref_40","unstructured":"American Association for the Study of Liver Diseases (AASLD), and Infectious Diseases Society of America (IDSA) (2022). HCV Testing and Linkage to Care. Management of Unique & Key Populations with HCV Infection, IDSA. Available online: https:\/\/www.hcvguidelines.org\/evaluate\/testing-and-linkage."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Hartley, C., Van, T., and Karnsakul, W. (2024). Direct-Acting Antiviral Agents in Prevention of Maternal-Fetal Transmission of Hepatitis C Virus in Pregnancy. Pathogens, 13.","DOI":"10.3390\/pathogens13060508"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/S2666-5247(20)30062-8","article-title":"Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: A phase 1 pharmacokinetic study","volume":"1","author":"Chappell","year":"2020","journal-title":"Lancet Microbe"},{"key":"ref_43","first-page":"S292","article-title":"Treatment of chronic hepatitis C with ledipasvir\/sofosbuvir combination during pregnancy","volume":"12","author":"Yattoo","year":"2018","journal-title":"Hepatol. Int."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6902a1","article-title":"CDC Recommendations for Hepatitis C Screening Among Adults\u2014United States, 2020","volume":"69","author":"Schillie","year":"2020","journal-title":"MMWR Recomm. Rep."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Network TEPHCV (2005). Three broad modalities in the natural history of vertically acquired hepatitis C virus infection. Clin. Infect. Dis., 41, 45\u201351.","DOI":"10.1086\/430601"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0168-8278(99)80368-7","article-title":"Hepatitis C: The clinical spectrum of the disease","volume":"31","author":"Marcellin","year":"1999","journal-title":"J. Hepatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1002\/hep.31830","article-title":"The 2020 Nobel Prize for Medicine or Physiology for the Discovery of Hepatitis C Virus: A Triumph of Curiosity and Persistence","volume":"74","author":"Ghany","year":"2021","journal-title":"Hepatology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/hep.510230202","article-title":"Hepatitis C virus: Detection of intracellular virus particles by electron microscopy","volume":"23","author":"Shimizu","year":"1996","journal-title":"Hepatology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0065-3527(08)00002-X","article-title":"Cutting the gordian knot-development and biological relevance of hepatitis C virus cell culture systems","volume":"71","author":"Gottwein","year":"2008","journal-title":"Adv. Virus Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1073\/pnas.89.8.3468","article-title":"Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: Potential role in chronic HCV infections","volume":"89","author":"Weiner","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1006\/viro.1993.1378","article-title":"A structurally flexible and antigenically variable N-terminal domain of the hepatitis C virus E2\/NS1 protein: Implication for an escape from antibody","volume":"195","author":"Taniguchi","year":"1993","journal-title":"Virology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF00945027","article-title":"Comparative features of hepatitis C virus infection in humans and chimpanzees","volume":"19","author":"Walker","year":"1997","journal-title":"Springer Semin. Immunopathol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1074-7613(00)80044-8","article-title":"Analysis of a successful immune response against hepatitis C virus","volume":"10","author":"Cooper","year":"1999","journal-title":"Immunity"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1084\/jem.191.9.1499","article-title":"Analysis of successful immune responses in persons infected with hepatitis C virus","volume":"191","author":"Lechner","year":"2000","journal-title":"J. Exp. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1172\/JCI118842","article-title":"Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response","volume":"98","author":"Missale","year":"1996","journal-title":"J. Clin. Investig."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1084\/jem.180.3.933","article-title":"Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope","volume":"180","author":"Bertoletti","year":"1994","journal-title":"J. Exp. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1126\/science.270.5240.1360","article-title":"Cytotoxic T lymphocyte lysis inhibited by viable HIV mutants","volume":"270","author":"Meier","year":"1995","journal-title":"Science"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/S0016-5085(98)70268-9","article-title":"Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity","volume":"115","author":"Tsai","year":"1998","journal-title":"Gastroenterology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1084\/jem.20030239","article-title":"Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection","volume":"197","author":"Shoukry","year":"2003","journal-title":"J. Exp. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1126\/science.1088774","article-title":"HCV persistence and immune evasion in the absence of memory T cell help","volume":"302","author":"Grakoui","year":"2003","journal-title":"Science"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1002\/hep.27013","article-title":"Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses","volume":"59","author":"Osburn","year":"2014","journal-title":"Hepatology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1073\/pnas.0607026104","article-title":"Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C","volume":"104","author":"Pestk","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"10149","DOI":"10.1073\/pnas.0403519101","article-title":"Neutralizing antibody response during acute and chronic hepatitis C virus infection","volume":"101","author":"Logvinoff","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1002\/hep.22244","article-title":"Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain","volume":"47","author":"Vanwolleghem","year":"2008","journal-title":"Hepatology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/hep.24171","article-title":"In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus","volume":"53","author":"Meuleman","year":"2011","journal-title":"Hepatology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1056\/NEJMoa2023345","article-title":"Randomized Trial of a Vaccine Regimen to Prevent Chronic HCV Infection","volume":"384","author":"Page","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2150132720969554","DOI":"10.1177\/2150132720969554","article-title":"Impact of the 2020 COVID-19 Pandemic on Ambulatory Hepatitis C Testing","volume":"11","author":"Sperring","year":"2020","journal-title":"J. Prim. Care Community Health"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1136\/medhum-2016-011099","article-title":"A dirty little secret: Stigma, shame and hepatitis C in the health setting","volume":"43","author":"Northrop","year":"2017","journal-title":"Med. Humanit."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"7880","DOI":"10.3748\/wjg.v19.i44.7880","article-title":"Burden of pediatric hepatitis C","volume":"19","author":"Kamal","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.idc.2018.02.010","article-title":"Hepatitis C Virus Diagnosis and the Holy Grail","volume":"32","author":"Applegate","year":"2018","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_71","unstructured":"(2024, December 24). Hoping for Hepatitis C Elimination Vol 4 August 2023 Copyright \u00a9 2023 The Author(s). Published by Elsevier Ltd. This Is an Open Access Article Under the CC BY 4.0 License. Available online: www.thelancet.com\/microbe."},{"key":"ref_72","unstructured":"(2024, December 24). MEMORANDUM OF UNDERSTANDING Between the World Health Organization, 20 Avenue Appia, 1211 Geneva, Switzerland (\u201cWHO\u201d) and Center for Disease Analysis Foundation (CDAF). Available online: https:\/\/cdafound.org\/documents\/WHO%20MOU.pdf."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Doyle, O.M., Leavitt, N., and Rigg, J.A. (2020). Finding undiagnosed patients with hepatitis C infection: An application of artificial intelligence to patient claims data. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-67013-6"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41746-024-01318-y","article-title":"Phenotyping people with a history of injecting drug use within electronic medical records using an interactive machine learning approach","volume":"7","author":"Nguyen","year":"2024","journal-title":"NPJ Digit. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1097\/HEP.0000000000000343","article-title":"Human liver organoids: From generation to applications","volume":"79","author":"Afonso","year":"2024","journal-title":"Hepatology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1242\/dev.118570","article-title":"Modeling mouse and human development using organoid cultures","volume":"142","author":"Huch","year":"2015","journal-title":"Development"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e20220010","DOI":"10.1002\/SMMD.20220010","article-title":"Recent advances in liver-on-chips: Design, fabrication, and applications","volume":"2","author":"Qiu","year":"2023","journal-title":"Smart Med."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/14\/1\/11\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:55:45Z","timestamp":1760115345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/14\/1\/11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,29]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["pathogens14010011"],"URL":"https:\/\/doi.org\/10.3390\/pathogens14010011","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,29]]}}}